Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis.

OBJECTIVE The aim of our study was to investigate clinical and histopathological findings in adult DM patients positive for anti-Mi2 (anti-Mi2+) antibodies compared with DM patients negative for anti-Mi2 (anti-Mi2-). METHODS Clinical data of adult DM patients, who fulfilled EULAR/ACR 2017 classification criteria, were gathered from electronic medical records of three tertiary Rheumatology Units. Histopathological study was carried out on 12 anti-Mi2+ and 14 anti-Mi2- muscle biopsies performed for diagnostic purpose. Nine biopsies from immune mediated necrotizing myopathy (IMNM) patients were used as control group. RESULTS Twenty-two anti-Mi2+ DM [90.9% female, mean age 56.5 (15.7) years] were compared with 69 anti-Mi2- DM patients [71% female, mean age 52.4 (17) years]. Anti-Mi2+ patients presented higher levels of serum muscle enzymes than anti-Mi2- patients [median (IQR) creatine-kinase fold increment: 16 (7-37)vs 3.5 (1-9.9), P <0.001] before treatment initiation. Moreover, a trend towards less pulmonary involvement was detected in anti-Mi2+ DM (9.1% vs 30.4%, P =0.05), without any case of rapidly progressive interstitial lung disease. At muscle histology, anti-Mi2+ patients showed more necrotic/degenerative fibres than anti-Mi2- patients [mean 5.3% (5) vs 0.8% (1), P <0.01], but similar to IMNM [5.9% (6), P >0.05]. In addition, the endomysial macrophage score was similar between anti-Mi2+ and IMNM patients [mean 1.2 (0.9) vs 1.3 (0.5), P >0.05], whereas lower macrophage infiltration was found in anti-Mi2- DM [mean 0.4 (0.5), <0.01]. CONCLUSIONS Anti-Mi2+ patients represent a specific DM subset with high muscle damage. Histological hallmarks were a higher prevalence of myofiber necrosis, endomysial involvement and macrophage infiltrates at muscle biopsy.

[1]  V. Jooste,et al.  Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy. , 2020, Journal of the American Academy of Dermatology.

[2]  Guochun Wang,et al.  Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis , 2020, European Journal of Dermatology.

[3]  Wei Zhang,et al.  Perimysial microarteriopathy in dermatomyositis with anti‐nuclear matrix protein‐2 antibodies , 2020, European journal of neurology.

[4]  A. Mammen,et al.  More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies , 2019, Neurology.

[5]  J. Lamb,et al.  239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018 , 2019, Neuromuscular Disorders.

[6]  I. Nishino,et al.  Classification of idiopathic inflammatory myopathies: pathology perspectives. , 2019, Current opinion in neurology.

[7]  S. Shinjo,et al.  Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis , 2019, Advances in Rheumatology.

[8]  G. Shaddick,et al.  Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients , 2019, Journal of autoimmunity.

[9]  T. Jacques,et al.  Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features , 2019, Neuropathology and applied neurobiology.

[10]  M. Mahler,et al.  In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy , 2018, Annals of the rheumatic diseases.

[11]  E. Zampeli,et al.  Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies , 2018, Clinical Rheumatology.

[12]  A. Mammen,et al.  Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies , 2018, Neurology.

[13]  V. Werth,et al.  Classification of myositis , 2018, Nature Reviews Rheumatology.

[14]  P. Hufnagl,et al.  Necrosis in anti-SRP+ and anti-HMGCR+myopathies , 2018, Neurology.

[15]  P. Lachenbruch,et al.  2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups , 2017, Annals of the rheumatic diseases.

[16]  E. Chan,et al.  A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy , 2017, Clinical Reviews in Allergy & Immunology.

[17]  A. Hida,et al.  Anti-TIF1-&ggr; antibody and cancer-associated myositis: A clinicohistopathologic study , 2016, Neurology.

[18]  A. Tincani,et al.  Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. , 2016, Journal of immunological methods.

[19]  P. Hufnagl,et al.  Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: Common Interferon Signature but Distinct NOS2 Expression. , 2016, The American journal of pathology.

[20]  F. Iannone,et al.  Do dermatomyositis and polymyositis affect similar thigh muscles? A comparative MRI-based study. , 2016, Clinical and experimental rheumatology.

[21]  A. Mammen,et al.  The composition of cellular infiltrates in anti‐HMG‐CoA reductase‐associated myopathy , 2015, Muscle & nerve.

[22]  A. Mammen,et al.  The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis , 2014, The Journal of Rheumatology.

[23]  Chung-Jen Chen,et al.  Inflammatory Muscle Diseases. , 2015, The New England journal of medicine.

[24]  A. Mammen,et al.  205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies Part II 28–30 March 2014, Naarden, The Netherlands , 2015, Neuromuscular Disorders.

[25]  J. Humphreys,et al.  How Do We Classify Rheumatoid Arthritis in Established Disease — Can We Apply the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria? , 2014, The Journal of Rheumatology.

[26]  P. Brigidi,et al.  The Three Genetics (Nuclear DNA, Mitochondrial DNA, and Gut Microbiome) of Longevity in Humans Considered as Metaorganisms , 2014, BioMed research international.

[27]  P. Rovere-Querini,et al.  Macrophage Plasticity in Skeletal Muscle Repair , 2014, BioMed research international.

[28]  M. Trojano,et al.  Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis , 2013, Neuropathology and applied neurobiology.

[29]  S. Marie,et al.  Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease , 2013, Annals of the rheumatic diseases.

[30]  F. Souza,et al.  Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis , 2013, Clinics.

[31]  F. Heppner,et al.  Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. , 2012, The American journal of pathology.

[32]  B. Feldman,et al.  Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies , 2010, Arthritis care & research.

[33]  A. Mammen,et al.  Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. , 2009, Arthritis and rheumatism.

[34]  A. Brunn,et al.  Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities? , 2009, Acta Neuropathologica.

[35]  S. Marie,et al.  International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. , 2007, Arthritis and rheumatism.

[36]  J. Vencovský,et al.  Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen , 2006 .

[37]  E. Gabrielson,et al.  Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy , 2005, The Journal of experimental medicine.

[38]  F. Hanefeld,et al.  Monocyte/macrophage differentiation in dermatomyositis and polymyositis , 2004, Muscle & nerve.

[39]  I. Targoff,et al.  The association between Mi-2 antibodies and dermatomyositis. , 1985, Arthritis and rheumatism.